Vertex Pharmaceuticals Incorpor
417.21-5.18 (-1.23%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · VRTX · USD
Key Stats
Market Cap
106.97BP/E (TTM)
29.67Basic EPS (TTM)
14.06Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Vertex Pharmaceuticals posted solid Q2 FY2025 results, with net product revenues climbing 11% year-over-year to $2.9 billion, fueled by 4% growth in TRIKAFTA/KAFTRIO to $2.6 billion and initial sales from ALYFTREK, CASGEVY, and JOURNAVX launches. Gross margin held steady at 86%, while operating income surged to $1.2 billion from a $3.5 billion loss last year, thanks to the absence of the $4.4 billion Alpine acquisition charge; diluted EPS rose to $3.99 from a $13.92 loss. Cash from operations hit $1.9 billion year-to-date, bolstering the $12.0 billion liquidity position with no debt drawn on the $500 million revolver. Early pipeline momentum shines in CF and autoimmune programs. Yet competition in gene therapies looms large.
8-K
Vertex Q2 revenue surges 12%
Vertex Pharmaceuticals reported Q2 2025 revenue of $2.96 billion, up 12% from last year, fueled by cystic fibrosis drugs and early sales from CASGEVY and JOURNAVX launches. The company reiterated full-year guidance of $11.85 to $12 billion, highlighting pipeline progress in pain, diabetes, and kidney diseases. Chief Scientific Officer David Altshuler plans to retire August 1, 2026; Mark Bunnage steps in February 2026. Leadership transition ensures continuity amid robust growth.
8-K
Vertex boosts buyback to $4.8B
Vertex Pharmaceuticals' board authorized a new $4.0 billion stock repurchase program on May 19, 2025, with no expiration date and flexibility to pause anytime based on market conditions. Combined with $775 million left from the 2023 program, this boosts total buyback capacity to $4.775 billion. Repurchases will occur opportunistically on the open market or via private deals. This signals strong confidence in the company's value amid biotech volatility.
8-K
Vertex annual meeting outcomes
Vertex Pharmaceuticals' shareholders overwhelmingly elected 11 directors, including Reshma Kewalramani and Jeffrey Leiden, at the May 14, 2025 annual meeting, securing board continuity through 2026. They ratified Ernst & Young as auditors for 2025 and approved executive compensation on an advisory basis. Yet a shareholder push against excessive golden parachutes failed decisively. Strong support signals investor confidence in governance.
10-Q
Q1 FY2025 results
Vertex Pharmaceuticals posted solid Q1 results, with total revenues climbing 3% year-over-year to $2,770.2 million, driven by TRIKAFTA/KAFTRIO's 2% gain to $2,535.5 million and ALYFTREK's debut at $53.9 million, while other CF products dipped 17%. Operating income fell 45% to $630.1 million due to a $379.0 million intangible impairment on the discontinued VX-264 T1D program, yet net income held at $646.3 million with diluted EPS of $2.49, down from $4.21, reconciling cleanly to 259.5 million shares. Gross margin stayed steady at 87%, but R&D expenses surged 24% to $979.7 million on pipeline investments, including JOURNAVX launch and povetacicept trials. Cash flow from operations generated $818.9 million, bolstering liquidity to $11.4 billion with no debt drawn on the $500 million revolver; free cash flow (derived) reached $778.2 million after $40.7 million capex. The Zai Lab deal added $10.0 million in other revenues for povetacicept rights in Asia. Competition in gene therapies poses ongoing risks.
ATXS
Astria Therapeutics, Inc.
12.60+0.13
BMRN
BioMarin Pharmaceutical Inc.
51.86-1.63
KALV
KalVista Pharmaceuticals, Inc.
10.96-0.17
KYTX
Kyverna Therapeutics, Inc.
7.17-0.44
LXRX
Lexicon Pharmaceuticals, Inc.
1.33-0.04
SION
Sionna Therapeutics, Inc.
37.52-1.93
TRDA
Entrada Therapeutics, Inc.
6.89-0.46
VERA
Vera Therapeutics, Inc.
29.36-0.60
VRNA
Verona Pharma plc
106.91+0.00
XRTX
XORTX Therapeutics Inc.
0.65+0.02